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Summary
Primary hyperparathyroidism is an endocrine disorder fea-
tured by an excessive and unregulated secretion of parathy-
roid hormone from one or more parathyroid glands. General-
ly, it can occur at any age, but it is seen most commonly in
the sixth decade of life. It represents a rare endocrine dis-
ease in children and young adults and its occurrence in
these subjects strongly suggest the possibility of facing a
hyperparathyroidism familial syndrome. Molecular genetics
have provided new acquisitions on parathyroid tumorigene-
sis in the last decade. Mutations in specific genes have been
demonstrated to account for the parathyroid tissue out-
growth. The availability of specific DNA testing has improved
diagnostic accuracy and simplified family monitoring in
many cases. Here, a brief review on clinical, pathological and
genetic aspects of primary hyperparathyroidism in the set-
ting of hereditary forms of the disease is treated. 
KEY WORDS: primary hyperparathyroidism, hypercalcemia, hereditary hy-
perparathyroidism, clinical management, DNA testing.
Introduction
Primary hyperparathyroidism (PHPT) is a disorder featured by
an excessive and unregulated secretion of parathyroid hor-
mone (PTH) from one or more parathyroid glands. Clinical di-
agnosis relies on the two major biochemical hallmarks of the
disease: hypercalcemia and elevated circulating concentra-
tions of PTH. Generally, PHPT can occur at any age, but it is
seen most commonly in the sixth decade of life. Overall, PHPT
has a prevalence of 3/1000 in the general population (1). The
female:male ratio has been reported to be 3:1 and women
may exhibit PHPT clinical expression in the first menopausal
decade, between 50 and 60 years (2). PTH hypersecretion is
generally determined by one or more parathyroid glands and
the most frequent histopathological picture accounting for PH-
PT is represented by a solitary benign adenoma, nearly 80%
of cases, and less frequently multiple adenomas, hyperplasia
of all parathyroid glands, observed in 15-20% of PHPT pa-
tients, and carcinoma occur. The latter represents no more
than 0.5% of PHPT cases (3). PHPT, usually, is a rare en-
docrine disease in children and young adults and when pre-
sent in these subjects is quite always in the context of a hy-
perparathyroidism familial syndrome. Contrarily to sporadic
PHPT, parathyroid hyperplasia is commonly associated to
hereditary forms of PHPT, such as Multiple Endocrine Neopla-
sia type 1 (MEN1) and type 2 (MEN2) syndromes, Familial
Isolated Hyperparathyroidism syndrome (FIHPT), Hyper-
parathyroidism-Jaw tumors syndrome (HPT-JT), Familial
Hypocalciuria Hypercalcemia (FHH) syndrome, Neonatal Se-
vere Hyperparathyroidism (NSHPT) syndrome and Autosomal
Dominant Moderate hyperparathyroidism (ADMH) syndrome
(Table I). 
New important molecular insights on parathyroid tumorigenesis
have been acquired in the last decade. This is particularly true
for hereditary forms of primary hyperparathyroidism where mu-
tations in specific genes, mainly anti-oncogenes, account for
the parathyroid tissue outgrowth.
Pathophysiological aspects of PHPT
Molecular genetic studies contributed to unravel a wide spec-
trum of molecular mechanisms underlying parathyroid tumori-
genesis. PHPT pathophysiology can be briefly summarized as
it follows:
1. Disorder of cell proliferation rate caused by alterations of
several genetic mechanisms with clonal loss or gain of cell
function, as clearly demonstrated by molecular genetic stud-
ies (4).
2. Disorder of the extracellular calcium-dependent set-point
that causes the loss of the normal feedback control on PTH
production and secretion by extracellular calcium concentra-
tions (5).
Finally, a past history of external neck irradiation in childhood
should also be taken into consideration (6).
Differently from other endocrine tumors, such as pituitary and
thyroid neoplasms, parathyroid abnormal growth does not
compress the nearby tissues, partly explaining the asympto-
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Table I - Clinical syndromes of familial forms of primary hyper-
parathyroidism.
Multiple Endocrine Neoplasia type 1 (MEN1)
Multiple Endocrine Neoplasia type 2A (MEN2A)
Familial Isolated Primary hyperparathyroidism (FIHPT)
Hyperparathyroidism- Jaw tumors (HPT-JT)
Familial Hypocalciuric Hypercalcemia (FHH)/Neonatal Severe Hy-
perparathyroidism (NSHPT)
Autosomal Dominant Moderate Hyperparathyroidism (ADMH)
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matic outcome of PHPT for several years before diagnosis. 
Genetic aspects in familial forms of PHPT
Molecular genetics strongly contributed to clearly evidence that
PHPT may also occur as a familial cluster (Table I). In Table II
familial hyperparathyroid disorders with their main genetic fea-
tures are briefly summarized. In any case, each of the following
described syndromes should be clinically approached through
a differential diagnosis. In deed, a differential diagnosis will in-
clude an integrating approach to all the hereditary forms of PH-
PT.
MEN1
MEN1 (OMIM 131100) is a complex tumor-predisposing disor-
der inherited in an autosomal dominant manner with a high de-
gree of penetrance, nearly 100% within 50 years of age. The
syndrome exhibits a high grade of clinical variability, also in
members from the same affected family. More than 20 combi-
nations of both endocrine and nonendocrine tumors have been
reported in MEN1 patients, with three endocrine localizations
constituting the “typical” clinical features of this syndrome: mul-
tiple tumors of parathyroid glands (generally all the parathyroid
glands), pituitary adenomas and tumors of the neuroendocrine
cells in the gastroenteric tract (7). Advances in molecular biolo-
gy and genetics have led to the identification of the specific ge-
netic defect, at chromosome 11q13 (Table II), improving the
understanding and ability to early diagnosis this syndrome (8). 
MEN1-associated PHPT
MEN1-PHPT represents the most common endocrinopathy as-
sociated to MEN1 syndrome, accounting for the 2-4% of global
PHPT forms and it represents the first clinical expression of
MEN1 syndrome in approximately 90% of individuals (7). It
does not exhibit sex prevalence and its age onset is typically
between 20 and 25 years (Table II), three decades earlier than
the sporadic cases of PHPT (9, 10). Its penetrance reaches
100% with age and all MEN1 affected individuals are expected
to have hypercalcemia by age 50 years.
MEN1-PHPT is often mild and asymptomatic with biochemical
evidence of hypercalcemia often detected in the course of
evaluation of individuals known to have or be at risk for MEN1
syndrome. However, even if the MEN1-associated PHPT is fre-
quently asymptomatic for a long period of time, a reduced bone
mass can be observed in hyperparathyroid women as early as
35 years of age (11). 
The common clinical manifestations of hypercalcemia are simi-
lar to those observed in nonhereditary sporadic form of PHPT.
However, it must be taken into account that hypercalcemia
may increase the secretion of gastrin from a gastrinoma, pre-
cipitating and/or exacerbating symptoms of Zollinger-Ellison
syndrome, a clinical picture frequently associated to MEN1
syndrome (10).
Pathology
MEN1 affected subjects generally exhibit a multiglandular
parathyroid disease with the enlargement of all the parathyroid
glands, rather than a single adenoma (Table II); they are con-
sidered to be tumors of clonal origin (10). Asymmetric and
asynchronic parathyroid outgrowth involves all parathyroid
glands in these patients and after 8-10 years from sub-total
parathyroidectomy a 50% of recurrence of PHPT has been ob-
served. This could be due to an onset of a new tumor in the
context of the parathyroid tissue remnant or, alternatively, to
the growth of an unremoved tumor (10). Malignant progression
of parathyroid tumors is not a clinical feature observed in “clas-
sic” MEN1 syndrome.
Molecular aspects
Germline inactivating mutations of MEN1 gene have been
found in most of the affected from MEN1 kindreds (Table II).
Recent advances on pathophysiological roles of menin, the
protein product of MEN1 gene, disclose the existence of an in-
tricate network composed by several molecular partners inter-
acting with menin: Smad3, TGFβ, JUND, GFAP, vimentin, NF-
kB, NM23H1, ERK, JUNK, Elk-1 and c-Fos (12-24). However,
it is still completely unknown how mutations in menin cause tu-
morigenesis, nor is the function of menin. Menin may play dif-
ferent roles in different tissues interacting with such different
proteins, but also the interacting proteins of such a molecular
network may have a role in both the onset and progression of
MEN1-associated tumors.
However, MEN1 parathyroid tumorigenesis has been widely
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Table II - Chromosomal localization and genetic defects underlying each familial form of hereditary hyperparathyroidism.
Syndrome/OMIM#° Chromosomal localization Gene/activity Type of germline mutation
MEN1/131100 11q13 MEN1/oncosoppressor Inactivating
MEN2A/171400 10q11.1 RET/proto-oncogene Activating
FIHPT/145000 11q13*, 1q25-q31*, MEN1/oncosoppressor, Inactivating for MEN1, 
3q13.3-q21*, HRPT2/oncosoppressor, HRPT2, and CaSR genes
and still unknown loci CaSR/GPCR
and still unknown genes
HPT-JT/607393 1q25-q31 HRPT2/oncosoppressor Inactivating
FHH-NSHPT/145980-239200 3q13.3-q21 CaSR/GPCR Inactivating
ADMH/601199 3q13.3-q21 CaSR/GPCR Atypical inactivating 
° OMIM: Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=omim)
*  Only a subset of families affected by FIHPT map to 11q13, or 1q25-q31, or 3q13.3-q21 loci. Mutations have been described in MEN1, HRPT2 and CaSR
genes.
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demonstrated to progress through the inactivation of the “wild
type” allele of MEN1 gene, a tumor suppressor gene, at somat-
ic level indirectly evidenced as loss of heterozygosity (LOH) at
11q13 or intragenic DNA markers (25-27). After the cloning of
MEN1 gene the early detection of asymptomatic carriers dra-
matically decreases the morbidity and mortality of MEN1 syn-
drome, providing the opportunity to initiate appropriate treat-
ment at early stages.
Treatment of MEN1-PHPT manifestations
Neck surgery still represents the elective treatment of this form
of PHTP. However, the use of bone anti-resorptive agents
should be considered prior to surgery, in order to both reduce
hypercalcemia and limit PTH-dependent bone resorption. 
No general consensus has been reached on which technique
could be the optimal surgical approach in MEN1-associated PH-
PT. It may be treated with either subtotal parathyroidectomy (re-
moval of 7/8 of the parathyroid tissue) or cryopreservation of
parathyroid tissue or total parathyroidectomy and autotransplan-
tation of parathyroid tissue (28) (Table III). As above mentioned,
it has been determined that eight to twelve years after success-
ful subtotal parathyroidectomy, PHPT recurred in as many as
50% of euparathyroid individuals with MEN1 syndrome (10), like-
ly as the result of either new neoplasia arising in residual normal
tissue, or neoplasia progressing in the residual tissue. Elaraj et
al. (29) showed that subtotal and total parathyroidectomy result-
ed in longer recurrence-free intervals compared with lesser re-
section. Cumulative recurrence rates for procedures considering
a less than subtotal parathyroid resection were 8%, 31%, and
63% at one, five, and ten years, respectively, while for more ex-
tensive parathyroid resection, subtotal or total, the cumulative re-
currence rates were 0%, 20%, and 39% at one, five, and ten
years, respectively. Severe hypoparathyroidism exhibits a higher
incidence after total parathyroidectomy, supporting the use of
subtotal parathyroidectomy as the initial procedure of choice in
MEN1 syndrome (29). Biochemical assessment of serum con-
centration of PTH on the first day following subtotal or total
parathyroidectomy may result as a good predictor of residual
parathyroid function (30, 31). However, repeated measurements
of serum calcium concentration are also useful and less expen-
sive than measurement of the serum concentration of PTH (30).
If auto-transplantation of the parathyroid glands has been per-
formed, the serum concentration of PTH should be assessed
no earlier than two months post-operatively and then once a
year thereafter; serum concentration of PTH should be mea-
sured in separate, but simultaneous, blood samples, one from
the arm without and one from the arm with the parathyroid tis-
sue auto-transplantation. This procedure allows the physician
both to assess the function of the transplanted parathyroid tis-
sue and monitor for possible recurrence of hyperparathy-
roidism. Postoperative parathyroid localizing studies may be
helpful if hyperparathyroidism recurs.
Multiple Endocrine Neoplasia type 2A syndrome (MEN 2A)
MEN2A is a clinical variant of MEN2 syndrome (OMIM 171400)
and it specifically carries an increased risk for parathyroid ade-
noma or hyperplasia (Table I). Similarly to MEN1 also this syn-
drome is inherited in an autosomal dominant manner with a
high degree of penetrance and clinical variability. MEN2A vari-
ant is clinically characterized by the occurrence of medullary
thyroid carcinoma (MTC), nearly in the 100% of affected sub-
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Table III - Main clinical features of various forms of hereditary hyperparathyroidism.
Syndrome Age of onset Parathyroid glands Pathology Treatment
(yr) involvement
MEN1 20-25 Multiglandular Hyperplasia/ SPTX or TPTX with autologous reimplantation +
Adenoma(s) transcervical thymectomy
MEN2A >30 Single/ Multiple adenomas/ Resection of only enlarged glands, 
Multiglandular Hyperplasia SPTX, TPTX with autologous reimplantation
FIHPT N. R. Single/ Single, Single disease: parathyroid adenomectomy
Multiglandular Multiple adenoma(s) Multiglandular disease: SPTX or TPTX 
with autologous reimplantation
HPT-JT >30 Single/ Single or double adenoma Single disease: parathyroid adenomectomy
[(average age 32 Multiglandular (cystic parathyroid adenomatosis). Multiglandular disease: SPTX or TPTX
(ref. 28)] (generally two glands) Parathyroid carcinoma with autologous reimplantation.
in approximately 10-15% Carcinoma: Neck surgery, 
of affected individuals specifically an en bloc resection of primary tumor, 
as the only curative treatment
FHH/NSHPT All ages/ Multiglandular Mildly enlarged parathyroid FHH: patients do not benefit from surgery
at birth or within glands/Markedly hyperplastic of parathyroid lesions, but subtotal 
the first 6 months parathyroid glands parathyroidectomy can be performed in subjects 
developing symptomatic PHPT 
NSHPT: TPTX
ADMH 44.5±3.9 (ref. 99) Single/ Diffuse to nodular parathyroid Radical subtotal parathyroid resection
Multiglandular neoplasia with parathyroid remnants of 10-20 mg 
or TPTX with autologous reimplantation
Legend: SPTX=Subtotal parathyroidectomy; TPTX=Total parathyroidectomy.
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jects, pheochromocytoma, bilateral or unilateral, in 50% of pa-
tients, whereas the PHPT is described in 20-30% of MEN2A
cases (7).
MEN2A-associated PHPT
PHPT in MEN2A is less common than in MEN1 syndrome, oc-
curring in 20 to 30% of the patients (7).
MEN2A-associated PHPT may silently occur for several
decades. It is sustained by the presence by multiple adenomas
or, less frequently, parathyroid hyperplasia and it exhibits a
less aggressive behavior respect to the MEN1-associated PH-
PT, usually occurring after the third decade (53-56) (Table II).
Generally, MEN 2A-related HPT is also mild and asympto-
matic, with approximately 15-25% of the patients developing
clinical signs of their disease (57-59). 
As usual, the diagnosis of parathyroid abnormalities is made
when biochemical screening reveals simultaneously elevated
serum concentrations of calcium and PTH (60).
Annual biochemical screening is recommended in case of af-
fected individuals who have not had parathyroidectomy and
auto-transplantation (61). Moreover, it has been suggested that
only individuals with codon 634 mutations undergo annual
screening and that individuals carrying other mutations may be
screened every two to three years (7).
Pathology
MEN2A-PHPT is generally sustained by a single enlarged
parathyroid gland, although multiglandular neoplasia does oc-
cur, with single or multiple parathyroid adenomas, respectively,
or, less frequently, parathyroid hyperplasia (Table III).
Molecular aspects
RET proto-oncogene is the responsible gene (62) (Table II).
The most frequent activating germline mutations associated
with MEN2A-PHPT phenotype occur at the exon 11 level,
codon 634, representing also the most frequent mutated codon
accounting for more than 50% of MEN2A cases (7). The en-
coded product of RET consists of a membrane protein with the
function of a tyrosinkinase receptor for which 4 different ligands
have been described: Glial Derived Neurotrophic Factor
(GDNF), Artemin, Neurturin and Persephin (63).
The PHPT phenotype is present in 20-30% of MEN2A cases
carrying a mutation within codon 634. This is the most fre-
quently described intragenic mutation site (85% of MEN2 famil-
ial cases). Every RET mutation at codon 634, exon 11, results
in a higher incidence of PHPT and pheochromocytoma (64,
65). In vitro studies have demonstrated that the transforming
activity related to 634 cysteine residue mutation is 3-5 fold
higher than the ones at 609, 611, 618, or 620 codons (66).
Among the 634 codon mutations, it has been early described
that C634R (cysteine to arginine substitution) significantly cor-
relates to the PHPT occurrence (62), but more recently other
studies failed to confirm such a correlation (67, 68). Moreover,
it has been hypothesized that these mutations may exert a less
transforming effect on parathyroid tissue respect to thyroid C
cells (69).
Shuffenecker et al. (69) demonstrated in a population of
MEN2A patients that: a) the PHPT prevalence (19.9%) did not
significantly vary according to the type of 634 mutation; b) the
PHPT prevalence exhibits a high interfamilial variability; c) a
heterogeneity for the risk to develop PHPT exists (9%-34%);
and d) PHPT could potentially represent a precocious clinical
component of MEN2A syndrome: in 44% of MEN2A subjects
PHPT occurred before age of 30 years [whereas it has been
generally considered to occur after the third decade (53-56)]. In
a clinical series they reported a 2 years old girl with a C634Y
mutation (cysteine to tyrosine substitution) presenting with
MTC and PHPT. All that suggests the possible existence of tis-
sue-specific effects of RET mutations and, as previously re-
ported, the thyroid C-cells could be more sensitive to RET mi-
togenic effect than other endocrine cell types (69).
As for the MEN1 syndrome, malignant progression of parathy-
roid tumors does not represent a clinical feature of MEN2A.
However, a parathyroid carcinoma in a MEN2A affected indi-
vidual, with combination of C634Y mutation and LOH at chro-
mosomes 1, 2, 3p, and 16p, has been described. It has been
also hypothesized that multiple allelic deletions could account
for an aggressive behavior (71).
Treatment of MEN2A-PHPT manifestations
Indications and type of surgery (resection of only enlarged
glands, subtotal parathyroidectomy, parathyroidectomy with
autotransplantation) are similar to those in other patients with
the potential for multiple parathyroid tumors, although curative
resection can be less aggressive (28) (Table III). An European
multicentre retrospective clinical study did consider 60 patients
with MEN2A-PHPT undergone neck surgery between 1972
and 1993 (71), exhibiting a median age at diagnosis of PHPT
of 38 years. PHPT resulted to be asymptomatic in more than
80% of the patients, whereas 15% clinically exhibited
nephrolithiasis. Independently from the extent of resection,
94% of the patients were cured, although 13% showed persis-
tent hypocalcemia, 3% resulted with persistent hypercalcemia,
and 3% were lost in follow up. At 8-years of follow up, hyper-
calcemia still recurred in 12% of the patients, unrelated to the
extent of parathyroid tissue resection (28). As for MEN1-PHPT,
postoperative parathyroid localizing studies may be helpful if
hyperparathyroidism recurs (60).
Familial Isolated PHPT (FIHPT)
FIHPT (OMIM 145000) is a rare hereditary disorder character-
ized by uni- or multiglandular parathyroid lesions in the ab-
sence of hyperfunction in other endocrine tissues (Table I).
FIHPT is transmitted in an autosomal dominant manner (72).
Few large families have been shown to be linked to MEN1
gene (73-75), or to calcium sensing receptor (CaSR) gene mu-
tations (75), while other families exhibit a segregation of phe-
notype with DNA markers close by the Hyperparathyroidism-
Jaw tumors (HPT-JT) syndrome locus at 1q25-q32. Most of
FIHPT kindreds have currently an unknown genetic back-
ground (28) (Table II). To date, approximately over 100 FIHPT
families have been described (76, 77).
In deed, the clinical management of this form could be com-
plex, although the generic surgical principles of PHPT treat-
ment can be generally applied.
Pathology
Uni- or multiglandular involvement represents the most fre-
quent pathological picture underlying the parathyroid hyper-
function (Table III). Progression to malignancy have not been
reported for affected subjects with solitary parathyroid adeno-
ma from two FIHPT families mapped to the same region as the
HPT-JT syndrome on chromosome 1q21-q32 (78).
Molecular aspects
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No gene has yet been associated exclusively with FIHPT.
However, as mentioned above, FIHPT has been linked to mu-
tations in the MEN1, and CaSR genes, whereas in some fami-
lies genetic linkage to these loci was not established (28). All
this is consistent with a genetic and clinical heterogeneity of
this form of PHPT. Carpten et al. reported in a patient from one
of the two FIHPT families mapped to chromosome 1q21-q-32,
a mutation in HRPT2 gene, confirming the they are allelic to
the HPT-JT syndrome (79) (Table III).
Treatment of FIHPT manifestations
In a case of uniglandular disease, parathyroid adenomectomy
can be performed, whereas for multiglandular involvement a
subtotal parathyroidectomy or total parathyroidectomy, with au-
tologous reimplantation, can be considered (Table III). Of
course, FIHPT linked to mutations in MEN1 or HRPT2 genes
should be treated similarly to MEN1- and HPT-JT-associated
PHPT, respectively, since the patient may be from a kindred with
absent or low penetrance of other associated tumor types (28).
Hyperparathyroidism-Jaw Tumors (HPT-JT) syndrome 
HPT-JT (OMIM 607393) (80) is a rare autosomal dominantly
inherited disorder characterized by fibrous-osseous tumors of
mandible and/or maxilla (ossifying fibroma), Wilms’ tumor, pap-
illary renal carcinoma, polycystic kidney disease, renal cysts
and PHPT. The latter exhibits an aggressive behavior within
this syndrome and it is frequently sustained by parathyroid car-
cinoma (79, 81).
In the context of PHPT-related syndromes (Table I), HPT-JT
syndrome is one of the least common and relatively unknown
pictures, although not less interesting or important.
About 80% of patients present with PHPT (79), that may devel-
op in late adolescence or older. A reduced penetrance in fe-
males has been reported (82), and parathyroid carcinoma may
occur in approximately 10-15% of affected individuals (72, 79).
When compared to MEN1-related PHPT, HTP-JT syndrome
may run a more aggressive course: the patients tend to have
more severe hypercalcemia and hypercalcemic crisis could
represent the first clinical evidence. In order to monitor the
presence/absence of PHPT, HPT-JT patients should undergo
annual blood tests evaluating ionized calcium and intact
parathyroid hormone (iPTH) levels, beginning by 15 years of
age. However, it should be taken always into account, due to
their possible severity, that lesions in the maxilla, mandible,
kidney, and uterus should be carefully monitorized by imaging
studies (i.e. orthopantography of the face, perhaps once in
every 3 years, and annual abdominal ultrasound or computed
tomography scan).
Pathology
PHPT in HPT-JT syndrome generally consists of involvement
of one or two parathyroid glands (adenoma or double adeno-
ma) (Table III) that may be or may be not synchronously pre-
sent (78), differently from the MEN1-PHPT in which all glands
are frequently involved. Parathyroid carcinoma may occur in
approximately 10-15% of affected individuals (72, 79).
The high incidence of cystic figure in resected parathyroid
glands represents a classical pathological feature of parathy-
roid neoplasia in HPT-JT syndrome. In fact, due to frequent
identification of parathyroid recurring cystic adenomas this clin-
ical entity can be referred to also as familial cystic parathyroid
adenomatosis (83) (Table III). The jaw lesions typically associ-
ated to this syndrome have been reported to be histologically
distinct from the typical ones representing the bone disease
classically associated to PHPT (82, 84).
Molecular aspects
Very recently, the HRPT2 gene, responsible for this syndrome,
has been identified in the “tumor suppressor gene” parafi-
bromin, previously mapped at 1q25-q32 (Table II). This gene
appears to be involved also in the pathogenesis of sporadic
forms of PHPT (85). Fourteen germline inactivating mutations
of HPRT2 gene were identified in 26 kindreds (79) (Table II).
The gene encodes a protein of 531 amino acids, named parafi-
bromin, involved in the development of parathyroid tumors and
ossifying fibromas. To date, the protein does not exhibit any
homology to known protein domains. The gene appears to be
ubiquitously expressed in several human tissues such as kid-
ney, heart, liver, pancreas, skeletal muscles, brain and lung
(79). However, its role in development and tumorigenesis still
remains to be elucidated.
Loss of wild-type alleles in HPT-JT syndrome was found both in
renal (82) and parathyroid tumors (78, 84). These findings, to-
gether with the inactivating nature of the germline mutations
strongly suggest a tumor suppressive role for parafibromin. Such
LOH are not as frequent as reported in MEN1-related tumors.
To date, it has been no possible to describe a genotype-phe-
notype correlation and more data from other affected families
and from genetic studies are necessary to possibly determine
the eventual existence of such a correlation.
However, the possibility to perform DNA test provides the great
opportunity for an early identification of an asymptomatic gene
carrier who will receive the needed stringent clinical screening
procedures.
Treatment of HPT-JT-PHPT manifestations
As soon clinical evidence of PHPT as occurred, neck surgery
should be promptly performed. However, a general consensus
on which type of surgical approach should be adopted, if re-
moval of the enlarged gland with long-term follow-up or com-
plete parathyroidectomy followed by auto-transplantation to the
nondominant forearm has not been reached (86). For parathy-
roid carcinoma neck surgery, specifically an en bloc resection
of primary tumor, is the only curative treatment (Table III). Al-
ternatively, affected patients could undergo repetitive palliative
surgical exeresis of metastatic nodules.
Familial Hypercalcemia Hypocalciuria Syndrome (FHH)/
Neonatal Severe Hyperparathyroidism (NSHPT) 
FHH (OMIM 145980) (Table I) is a rare disorder inherited in au-
tosomal dominant manner and characterized in the adult by the
outcome of increased/normal levels of serum calcium, moderate
hypophosphoremia, increased/normal circulating PTH levels,
that are frequently inadequate when correlated to serum calcium
levels and an inappropriately low urinary calcium excretion (87).
The majority of patients with FHH are asymptomatic and do not
benefit from surgical resection of their mildly enlarged parathy-
roid that cannot correct the calcium-dependent PTH secretion
set-point abnormality (88, 89). FHH-related hypercalcemia is
highly penetrant at all ages (90). Generally, these patients show
relative hypocalciuria (urinary calcium/creatinine ratio typically
<0·01) in the presence of hypercalcemia and hyperparathy-
roidism due to inactivation of CaSR protein in renal tubules.
Moreover, a mild hypermagnesemia can be found (90, 91).
NSHPT (OMIM 239200) (Table I) generally represents the ho-
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mozygous form of FHH, in which PHPT occurs at birth or within
the first 6 months of life determining a severe symptomatic hy-
percalcemia, with skeletal manifestations of PHPT and if neck
surgery is not promptly performed a lethal outcome may occur. 
Pathology
PHPT in the setting of FHH is generally sustained by the pres-
ence of mildly enlarged parathyroid glands (88, 89), whereas
markedly hyperplastic parathyroid glands are a typical feature
of NSHPT-related PHPT (Table III).
Molecular aspects
Inactivating mutations, with a loss of function, of CaSR gene,
localized at chromosome 3q13-21, account for both the forms
(92, 93) (Table II). CaSR protein is a membrane protein con-
sisting of 1078 amino acids, mainly expressed by kidney and
parathyroid cells, belongs to the G proteins-coupled receptor
(GPCR) superfamily. The CaSR is able to sense small
changes in circulating calcium concentration and when activat-
ed it inhibits PTH secretion and renal tubule calcium reabsorp-
tion. The described mutations in FHH and NSHPT subjects are
prevalently localized in the calcium binding site of extracellular
portion of receptor. Inactivation of this GPCR protein results in
half-maximal inhibition of PTH secretion only at increased con-
centrations of serum calcium (calcium set-point), although the
magnitude of PTH suppression by increased serum calcium
concentrations is normal in patients with FHH (94). Somatic
mutations within the CaSR gene, which would explain impaired
function and altered receptor expression, have not been de-
tected both in sporadic and familial forms of parathyroid tumors
thus far (95, 96).
Treatment of FHH/NSHPT-PHPT manifestations
Although it is generally accepted that FHH patients do not ben-
efit from surgery of parathyroid lesions, subtotal parathyroidec-
tomy can be performed in subjects developing symptomatic
PHPT (Table III) who may have an underlying polyclonal
parathyroid cell hyperproliferation due to a heterozygous inacti-
vation of CaSR (28) or to another hypothetical acquired genetic
defect in a different gene (97). When performed the neck
surgery in FHH subjects may include subtotal parathyroidecto-
my leaving 10–20 mg of parathyroid tissue in order to achieve
normocalcemia (Table III). In all cases, cryopreservation of
parathyroid tissue should be considered (28). Total parathy-
roidectomy must be performed in the first months of life (98) in
NSHPT affected infants (Table III).
Familial Hypercalcemia Hypercalciuria Syndrome or Auto-
somal Dominant Moderate Hyperparathyroidism (ADMH)
Carling et al. reported a large family with 20 members, from dif-
ferent generations, affected by this syndrome (OMIM 601199)
(99) (Table I). These subjects did exhibit hypercalcemia and hy-
percalciuria, with an inappropriately high serum PTH and mag-
nesium levels and with nephrolithiasis in a subset of patients.
Pathology
Uni-, multi-glandular involvement of parathyroid glands was
found and diffuse to nodular parathyroid neoplasia has been
reported on pathological examination (Table III).
Molecular aspects
DNA test revealed the presence of an atypical inactivating mu-
tation in the intra-cytoplasmic tail domain of CaSR in the
germline of affected subjects (Table II). LOH analysis revealed
allelic losses at various genetic loci, consistent with mono- or
oligoclonality of parathyroid tumors (88).
Treatment of ADMH-PHPT manifestations
Differently than classical FHH cases, radical subtotal parathy-
roid resection with parathyroid remnants of 10-20 mg or total
parathyroidectomy with autotransplantation (Table III) normal-
ized calcemia in 60% of affected. A persistent hypercalcemia
was noted in the 60% of patients (3/5) subjected to less radical
parathyroid surgical procedures. However, after an average
follow up of 5.1 years no patients with recurrent hypercalcemia
have been reported (28).
Conclusions
In general, an inherited hyperparathyroid syndrome should be
suspected in younger patients with PHPT, <40 years old or at
least two decades earlier than the sporadic counterpart, and/or
in patients with multiple parathyroid adenomas or hyperplasia
at surgery as seen in MEN1 or FHH syndromes, atypical
parathyroid adenomas, such as familial cystic parathyroid ade-
nomatosis, or parathyroid carcinoma as reported in HPT-JT
syndrome, and in presence of a family or past medical history
pointing to one of the described syndromes.
The availability of specific genetic testing for four of the syn-
dromes has improved diagnostic accuracy and simplified family
monitoring in many cases, but its current cost and limited ac-
cessibility require rationalization of its use.
Moreover, the cloning of several genes responsible for familial
PHPT syndrome has increased the possibilities for new basic
and clinical researches. Functional studies have to be per-
formed to understand the function of a specific gene, as also
the mechanisms by which its mutations lead to parathyroid tu-
morigenesis. A great help will come from the creation of specif-
ic animal models that will provide the possibility to manipulate
the mouse homologue of the gene(s). 
The advent of intraoperative PTH evaluation, as a routine
evaluation in many centers performing parathyroid surgery,
may be helpful for an optimal outcome of parathyroid surgery
for familial PHPT syndromes, although some controversies
are still existing concerning the rate of possible false-positive
results and the possibility of inadequate resection of parathy-
roid tissue in patients with multiglandular disease (28, 100,
101). In order to reduce the risk of false-positive results, spe-
cially in MEN1 patients, it has been suggested to apply more
stringent criteria in the threshold value of percentage reduc-
tion of PTH circulating levels prior to establish an adequate
excision of parathyroid tissue (102, 103). However, further
studies are needed to optimize rates of false-positive and
–negative results in the setting of familial PHPT to guide an
adequate extent of parathyroid tissue resection to achieve
postoperative long-term eucalcemia.
Finally, new acquisitions in the pathogenesis of familial PH-
PT will be extremely useful to examine the role of specific
genetic pathways in the sporadic counterparts. In particular,
it will be important to understand how specific gene muta-
tions, such as in HRPT2 gene, can contribute to malignant
progression in a distinct subset of parathyroid tumors. Mole-
cular techniques such as the microarray expression profile
analysis may recognize the existence of a sort of molecular
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signatures distinguished for each subset of familial parathy-
roid tumors, also contributing to define a genotype–pheno-
type correlation that could improve the clinical management
of this disease.
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